| Product Code: ETC7178746 | Publication Date: Sep 2024 | Updated Date: Nov 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Vasudha | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
In 2024, Fiji continued to rely on Australia, New Zealand, India, Bangladesh, and the USA as key exporters of large molecule drug substances for CDMO services. Despite a high concentration with a high Herfindahl-Hirschman Index (HHI), the market exhibited a moderate CAGR of 4.6% from 2020 to 2024. However, there was a notable decrease in growth rate from 2023 to 2024, with a -15.41% decline. This shift suggests potential market challenges or fluctuations that may impact the import landscape for large molecule drug substances in Fiji.

1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Fiji Large Molecule Drug Substance CDMO Market Overview |
3.1 Fiji Country Macro Economic Indicators |
3.2 Fiji Large Molecule Drug Substance CDMO Market Revenues & Volume, 2021 & 2031F |
3.3 Fiji Large Molecule Drug Substance CDMO Market - Industry Life Cycle |
3.4 Fiji Large Molecule Drug Substance CDMO Market - Porter's Five Forces |
3.5 Fiji Large Molecule Drug Substance CDMO Market Revenues & Volume Share, By Service, 2021 & 2031F |
3.6 Fiji Large Molecule Drug Substance CDMO Market Revenues & Volume Share, By Source, 2021 & 2031F |
3.7 Fiji Large Molecule Drug Substance CDMO Market Revenues & Volume Share, By End-user, 2021 & 2031F |
4 Fiji Large Molecule Drug Substance CDMO Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing demand for large molecule drugs in the pharmaceutical industry |
4.2.2 Growing trend of outsourcing drug substance manufacturing to contract development and manufacturing organizations (CDMOs) |
4.2.3 Advances in biotechnology leading to the development of more complex large molecule drugs |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements and quality standards in drug manufacturing |
4.3.2 High initial investment costs for setting up large molecule drug manufacturing facilities |
4.3.3 Competition from established CDMOs with strong track records in the market |
5 Fiji Large Molecule Drug Substance CDMO Market Trends |
6 Fiji Large Molecule Drug Substance CDMO Market, By Types |
6.1 Fiji Large Molecule Drug Substance CDMO Market, By Service |
6.1.1 Overview and Analysis |
6.1.2 Fiji Large Molecule Drug Substance CDMO Market Revenues & Volume, By Service, 2021- 2031F |
6.1.3 Fiji Large Molecule Drug Substance CDMO Market Revenues & Volume, By Contract Manufacturing, 2021- 2031F |
6.1.4 Fiji Large Molecule Drug Substance CDMO Market Revenues & Volume, By Clinical, 2021- 2031F |
6.1.5 Fiji Large Molecule Drug Substance CDMO Market Revenues & Volume, By Commercial, 2021- 2031F |
6.1.6 Fiji Large Molecule Drug Substance CDMO Market Revenues & Volume, By Contract Development, 2021- 2031F |
6.1.7 Fiji Large Molecule Drug Substance CDMO Market Revenues & Volume, By Cell Line Development, 2021- 2031F |
6.1.8 Fiji Large Molecule Drug Substance CDMO Market Revenues & Volume, By Process Development, 2021- 2031F |
6.2 Fiji Large Molecule Drug Substance CDMO Market, By Source |
6.2.1 Overview and Analysis |
6.2.2 Fiji Large Molecule Drug Substance CDMO Market Revenues & Volume, By Mammalian, 2021- 2031F |
6.2.3 Fiji Large Molecule Drug Substance CDMO Market Revenues & Volume, By Microbial, 2021- 2031F |
6.2.4 Fiji Large Molecule Drug Substance CDMO Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Fiji Large Molecule Drug Substance CDMO Market, By End-user |
6.3.1 Overview and Analysis |
6.3.2 Fiji Large Molecule Drug Substance CDMO Market Revenues & Volume, By Biotech Companies, 2021- 2031F |
6.3.3 Fiji Large Molecule Drug Substance CDMO Market Revenues & Volume, By CRO, 2021- 2031F |
6.3.4 Fiji Large Molecule Drug Substance CDMO Market Revenues & Volume, By Others, 2021- 2031F |
7 Fiji Large Molecule Drug Substance CDMO Market Import-Export Trade Statistics |
7.1 Fiji Large Molecule Drug Substance CDMO Market Export to Major Countries |
7.2 Fiji Large Molecule Drug Substance CDMO Market Imports from Major Countries |
8 Fiji Large Molecule Drug Substance CDMO Market Key Performance Indicators |
8.1 Average turnaround time for large molecule drug substance manufacturing |
8.2 Percentage of successful technology transfers for new drug substances |
8.3 Rate of adoption of innovative manufacturing technologies in large molecule drug production |
8.4 Number of new partnerships and collaborations with pharmaceutical companies for drug substance manufacturing |
8.5 Employee retention rate and skill development in specialized areas like bioprocessing |
9 Fiji Large Molecule Drug Substance CDMO Market - Opportunity Assessment |
9.1 Fiji Large Molecule Drug Substance CDMO Market Opportunity Assessment, By Service, 2021 & 2031F |
9.2 Fiji Large Molecule Drug Substance CDMO Market Opportunity Assessment, By Source, 2021 & 2031F |
9.3 Fiji Large Molecule Drug Substance CDMO Market Opportunity Assessment, By End-user, 2021 & 2031F |
10 Fiji Large Molecule Drug Substance CDMO Market - Competitive Landscape |
10.1 Fiji Large Molecule Drug Substance CDMO Market Revenue Share, By Companies, 2024 |
10.2 Fiji Large Molecule Drug Substance CDMO Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |